Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Valneva Announces the Sale of its Clinical Manufacturing Operations to Biological E

Published: Friday, June 07, 2013
Last Updated: Friday, June 07, 2013
Bookmark and Share
Next step in broadening an excellent strategic partnership.

Valneva SE has announced the signing of a binding term sheet to sell its Clinical Manufacturing Operations (CMO) in Nantes to Biological E, a leading Indian biopharmaceutical company.

The sale of this unit, which is dedicated to the manufacturing of clinical trial materials, is part of Valneva´s strategy to realize cost synergies of EUR 5 to 6 million annually following the merger of Intercell AG and Vivalis SA to create Valneva.

The divestment of the CMO facility is expected to contribute up to EUR 3 million cost savings to the annual merger-synergies.

In addition, Valneva will receive an undisclosed purchase price, exceeding the current book value of the facility.

Valneva and Biological E established a first partnership in 2005 for the development and commercialization of a novel Japanese Encephalitis vaccine for endemic regions, based on Valneva´s JEV technology.

The vaccine, which was successfully developed under this partnership, is being commercialized in India under the trade-name JEEV® and further territory expansions in the JE-endemic markets are planned. The CMO facility in Nantes will not be related to the JEV vaccine program.

Valneva and Biological E are also in discussions to potentially extend their strategic partnership into new vaccine development programs based on Valneva´s EB66® manufacturing platform.

The EB66® cell line is an advanced system for the production of a wide variety of human and veterinary viral and therapeutic vaccines.

Valneva remains the owner of the EB66® cell line and will continue to license it for human and veterinary product development to pharmaceutical and biotech companies and to propose EB66® process development services.

Thomas Lingelbach, President and Chief Executive Officer and Franck Grimaud, President and Chief Business Officer of Valneva, commented: “This agreement demonstrates that Valneva’s merger strategy to become a leading sustainable biotech company in antibodies and vaccines, is on track. We are pleased to broaden our excellent strategic partnership with Biological E with this transaction and believe that it will create additional opportunities for our two companies going forward.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Valvena, GSK Sign New R&D Collaboration
Valneva to supply process development services for EB66® -based Influenza vaccines.
Tuesday, February 09, 2016
Valneva Announces Agreements with VaxServe
U.S. distribution and marketing services agreements for Japanese encephalitis vaccine IXIARO®.
Thursday, November 12, 2015
Valneva Announces Approval of an EB66®-based Prototype Influenza Vaccine in Japan
The vaccine was developed by the Chemo-Sero Therapeutic Research Institute (Kaketsuken) in collaboration with GlaxoSmithKline using Valneva’s EB66® cell line.
Thursday, March 26, 2015
Valneva Announces Signing of an Exclusive License Agreement
Agreement on EB66® cell line for human and veterinary vaccines in People’s Republic of China.
Wednesday, March 18, 2015
Completion of Merger Between Vivalis and Intercell to Form Valneva
Creating a European biotech leader in vaccines and antibodies.
Thursday, May 30, 2013
Vivalis and Intercell Merge to form Valneva
Completion of merger process creates a European biotech leader in vaccines and antibodies.
Wednesday, May 29, 2013
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Overlooked Molecules Could Revolutionise our Understanding of the Immune System
Researchers have discovered that around one third of all the epitopes displayed for scanning by the immune system are a type known as ‘spliced’ epitopes.
Signaling Pathway Could Be Key to Improved Osteoporosis Treatment
Inhibition of SIK2 enzyme both stimulates bone formation and reduces bone breakdown in animal model.
Less Frequent Cervical Cancer Screening
HPV-vaccinated women may only need one screening every 5 to 10 years with screening starting later in life.
The Power Of Orthogonality In Assessing The Stability Of Biopharmaceuticals
By utilizing orthogonal techniques, researchers can maximize the secure application of all analytical results generated.
Dysfunction in Neuronal Transport Mechanism Linked to Alzheimer’s
Findings confirm mutation-caused problem but also reveal a new therapeutic target.
New Antibody Therapy Permanently Blocks SIV Infection
An international research team has developed an effective treatment strategy against the HIV-like Simian Immunodeficiency Virus (SIV) in rhesus macaques.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
DNA Vaccines Protect Monkeys Against Zika Virus
Two experimental Zika virus DNA vaccines developed by NIH scientists protected monkeys against Zika infection.
Rare Flu-Thwarting Mutation Discovered
Study finds protein mutation, that is encoded by influenza, causes the virus to lose any defence against the immune system.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos